Efficacy* O O O O
in O O O O
Older O O O O
Adults: O O O O
Now O O O O
in O O O O
Canada O O O O
[Sanofi O O O O
Pasteur](/news/sanofi-pasteur/) O O O O
13 O O O O
Oct, O O O O
2016, O O O O
08:00 O O O O
ET O O O O
[] O O O O
13 O O O O
Oct, O O O O
2016, O O O O
08:00 O O O O
ET O O O O
- O O O O
Canada's Reason 5 ScientificAuthority O
National Reason 5 ScientificAuthority O
Advisory Reason 5 ScientificAuthority O
Committee Reason 5 ScientificAuthority O
on Reason 5 ScientificAuthority O
Immunization Reason 5 ScientificAuthority O
(NACI) Reason 5 ScientificAuthority O
recognizes Reason 5 O O
superior Reason 5 O O
efficacy Reason 5 O O
of Reason 5 O O
high-dose Reason 5 O O
flu Reason 5 O O
vaccine Reason 5 O O
for Reason 5 O O
adults Reason 5 O O
+65 Reason 5 O O
years Reason 5 O O
compared Reason 5 O O
to Reason 5 O O
a Reason 5 O O
standard Reason 5 O O
dose Reason 5 O O
vaccine Reason 5 O O
- Reason 5 O O
TORONTO, Reason 5 O O
Oct. Reason 5 O O
13, Reason 4 O O
2016 Reason 4 O O
/CNW/ Reason 4 O O
- Reason 4 O O
Sanofi Reason 4 O O
Pasteur Reason 4 O O
announces Reason 4 O O
that Reason 4 O O
FLUZONE® Reason 4 O O
High-Dose Reason 4 O O
Influenza Reason 4 O O
(flu) Reason 4 O O
Vaccine Reason 4 O O
will Reason 4 O O
be Reason 4 O O
available Reason 4 O O
for Reason 4 O O
the Reason 4 O O
first Reason 4 O O
time Reason 4 O O
in Reason 4 O O
Canada Reason 4 O O
for Reason 4 O O
purchase Reason 4 O O
at Reason 4 O O
select Reason 4 O O
pharmacies Reason 4 O O
and Reason 4 O O
vaccination Reason 4 O O
clinics Reason 4 O O
across Reason 4 O O
the Reason 4 O O
country Reason 4 O O
starting Reason 4 O O
today. Reason 4 O O
As Reason 2 O O
the Reason 2 O O
immune Reason 2 O O
system Reason 2 O O
declines Reason 2 O O
with Reason 2 O O
age, Reason 2 O O
older Reason 2 O O
adults Reason 2 O O
do Reason 2 O O
not Reason 2 O O
respond Reason 2 O O
to Reason 2 O O
standard Reason 2 O O
dose Reason 2 O O
flu Reason 2 O O
vaccines Reason 2 O O
as Reason 2 O O
well Reason 2 O O
as Reason 2 O O
younger Reason 2 O O
adults.1,2 Reason 2 O O
FLUZONE® Reason 5 O O
High-Dose Reason 5 O O
Influenza Reason 5 O O
Vaccine Reason 5 O O
has Reason 5 O O
been Reason 5 O O
shown Reason 5 O O
to Reason 5 O O
generate Reason 5 O O
an Reason 5 O O
enhanced Reason 5 O O
vaccine-induced Reason 5 O O
immune Reason 5 O O
response Reason 5 O O
in Reason 5 O O
those Reason 5 O O
65 Reason 5 O O
years Reason 5 O O
of Reason 5 O O
age Reason 5 O O
and Reason 5 O O
older Reason 5 O O
compared Reason 5 O O
to Reason 5 O O
a Reason 5 O O
standard Reason 5 O O
dose Reason 5 O O
vaccine.,2,3 Reason 5 O O
Importantly, Reason 5 O O
a Reason 5 O O
large, Reason 5 O O
randomized, Reason 5 O O
clinical Reason 5 O O
trial Reason 5 O O
also Reason 5 O O
demonstrated Reason 5 O O
that Reason 5 O O
FLUZONE® Reason 5 O O
High-Dose Reason 5 O O
Influenza Reason 5 O O
Vaccine Reason 5 O O
provided Reason 5 O O
superior Reason 5 O O
efficacy Reason 5 O O
against Reason 5 O O
laboratory-confirmed Reason 5 O O
influenza Reason 5 O O
illness Reason 5 O O
compared Reason 5 O O
to Reason 5 O O
a Reason 5 O O
standard Reason 5 O O
dose Reason 5 O O
vaccine Reason 5 O O
in Reason 5 O O
adults Reason 5 O O
65 Reason 5 O O
years Reason 5 O O
of Reason 5 O O
age Reason 5 O O
and Reason 5 O O
older.2,3,4 Reason 5 O O
In Reason 5 O O
its Reason 5 O O
immunization Reason 5 O O
advisory Reason 5 O O
statement Reason 5 O O
for Reason 5 O O
the Reason 5 O O
upcoming Reason 5 O O
2016/2017 Reason 5 O O
influenza Reason 5 O O
season, Reason 5 O O
Canada's Reason 5 ScientificAuthority O
National Reason 5 ScientificAuthority O
Advisory Reason 5 ScientificAuthority O
Committee Reason 5 ScientificAuthority O
on Reason 5 ScientificAuthority O
Immunization Reason 5 ScientificAuthority O
(NACI) Reason 5 ScientificAuthority O
has Reason 5 O O
stated: Reason 5 O O
'Considering Reason 5 O O
the Reason 5 O O
burden Reason 5 O O
of Reason 5 O O
disease Reason 5 O O
associated Reason 5 O O
with Reason 5 O O
influenza Reason 5 O O
A Reason 5 O O
(H3N2) Reason 5 O O
and Reason 5 O O
the Reason 5 O O
evidence Reason 5 O O
of Reason 5 O O
superior Reason 5 O O
efficacy Reason 5 O O
of Reason 5 O O
high Reason 5 O O
dose Reason 5 O O
TIV Reason 5 O O
compared Reason 5 O O
to Reason 5 O O
standard Reason 5 O O
dose Reason 5 O O
TIV, Reason 5 O O
it Reason 5 O O
appears Reason 5 O O
that Reason 5 O O
high Reason 5 O O
dose Reason 5 O O
TIV Reason 5 O O
would Reason 5 O O
provide Reason 5 O O
the Reason 5 O O
greatest Reason 5 O O
benefit Reason 5 O O
to Reason 5 O O
the Reason 5 O O
65 Reason 5 O O
years Reason 5 O O
age Reason 5 O O
group'.3 Reason 5 O O
For O O O O
many O O O O
people, O O O O
recovering O O O O
from O O O O
influenza O O O O
infections O O O O
may O O O O
take O O O O
seven O O O O
to O O O O
ten O O O O
days.3 O O O O
However, O O O O
it O O O O
may O O O O
take O O O O
longer O O O O
for O O O O
adults O O O O
65 O O O O
years O O O O
of O O O O
age O O O O
and O O O O
older O O O O
to O O O O
recover O O O O
as O O O O
they O O O O
are O O O O
at O O O O
risk O O O O
of O O O O
developing O O O O
more O O O O
severe O O O O
complications O O O O
or O O O O
worsening O O O O
underlying O O O O
medical O O O O
conditions.3,5,6 O O O O
Further, O O O O
influenza O O O O
may O O O O
trigger O O O O
medical O O O O
events O O O O
like O O O O
strokes O O O O
and O O O O
heart O O O O
attacks O O O O
because O O O O
of O O O O
the O O O O
possible O O O O
destabilizing O O O O
effects O O O O
that O O O O
the O O O O
inflammatory O O O O
response O O O O
can O O O O
have O O O O
on O O O O
the O O O O
cardiovascular O O O O
system.6, O O O O
Where O O O O
to O O O O
get O O O O
high-dose O O O O
vaccine O O O O
At Reason 4 O O
this Reason 4 O O
time, Reason 4 O O
the Reason 4 O O
high-dose Reason 4 O O
influenza Reason 4 O O
vaccine Reason 4 O O
is Reason 4 O O
not Reason 4 O O
publicly Reason 4 O O
funded Reason 4 O O
but Reason 4 O O
is Reason 4 O O
available Reason 4 O O
for Reason 4 O O
purchase Reason 4 O O
at Reason 4 O O
some Reason 4 O O
pharmacies Reason 4 O O
or Reason 4 O O
vaccination Reason 4 O O
clinics. Reason 4 O O
To Reason 4 O O
find Reason 4 O O
out Reason 4 O O
where Reason 4 O O
you Reason 4 O O
can Reason 4 O O
purchase Reason 4 O O
this Reason 4 O O
vaccine, Reason 4 O O
enter Reason 4 O O
your Reason 4 O O
postal Reason 4 O O
code Reason 4 O O
in Reason 4 O O
the Reason 4 O O
locator Reason 4 O O
at Reason 4 O O
[www.fluhd.ca](http://www.fluhd.ca/). Reason 4 O O
About O O O O
FLUZONE® O O O O
High-Dose O O O O
Vaccine O O O O
FLUZONE® O O O O
High-Dose O O O O
is O O O O
a O O O O
trivalent O O O O
influenza O O O O
vaccine O O O O
that O O O O
contains O O O O
four O O O O
times O O O O
the O O O O
amount O O O O
of O O O O
hemagglutinin O O O O
(HA) O O O O
per O O O O
strain O O O O
as O O O O
compared O O O O
to O O O O
a O O O O
standard O O O O
dose O O O O
vaccine.2,4 O O O O
FLUZONE® Reason 4 O O
High-Dose Reason 4 O O
Influenza Reason 4 O O
Vaccine Reason 4 O O
is Reason 4 O O
indicated Reason 4 O O
for Reason 4 O O
active Reason 4 O O
immunization Reason 4 O O
against Reason 4 O O
influenza Reason 4 O O
caused Reason 4 O O
by Reason 4 O O
the Reason 4 O O
specific Reason 4 O O
strains Reason 4 O O
of Reason 4 O O
influenza Reason 4 O O
virus Reason 4 O O
contained Reason 4 O O
in Reason 4 O O
the Reason 4 O O
vaccine Reason 4 O O
in Reason 4 O O
adults Reason 4 O O
65 Reason 4 O O
years Reason 4 O O
of Reason 4 O O
age Reason 4 O O
and Reason 4 O O
older.2 Reason 4 O O
It Reason 4 O O
is Reason 4 O O
administered Reason 4 O O
as Reason 4 O O
a Reason 4 O O
single Reason 4 O O
0.5 Reason 4 O O
mL Reason 4 O O
injection Reason 4 O O
by Reason 4 O O
the Reason 4 O O
intramuscular Reason 4 O O
route.2 Reason 4 O O
Higher Reason 2 O O
rates Reason 2 O O
of Reason 2 O O
some Reason 2 O O
injection-site Reason 2 O O
and Reason 2 O O
systemic Reason 2 O O
reactions Reason 2 O O
were Reason 2 O O
observed Reason 2 O O
among Reason 2 O O
recipients Reason 2 O O
of Reason 2 O O
the Reason 2 O O
high-dose Reason 2 O O
vaccine Reason 2 O O
compared Reason 2 O O
to Reason 2 O O
a Reason 2 O O
standard-dose Reason 2 O O
vaccine, Reason 2 O O
but Reason 2 O O
most Reason 2 O O
reactions Reason 2 O O
were Reason 2 O O
mild Reason 2 O O
and Reason 2 O O
resolved Reason 2 O O
within Reason 2 O O
three Reason 2 O O
days.1,2,4 Reason 2 O O
FLUZONE® Reason 2 O O
High-Dose Reason 2 O O
Influenza Reason 2 O O
Vaccine Reason 2 O O
has Reason 2 O O
been Reason 2 O O
available Reason 2 O O
in Reason 2 O O
the Reason 2 O O
United Reason 2 O O
States Reason 2 O O
since Reason 2 O O
2009 Reason 2 O O
with Reason 2 O O
approximately Reason 2 O O
50 Reason 2 O O
million Reason 2 O O
doses Reason 2 O O
distributed. Reason 2 O O
For Reason 4 O O
more Reason 4 O O
information Reason 4 O O
about Reason 4 O O
FLUZONE® Reason 4 O O
High-Dose Reason 4 O O
Influenza Reason 4 O O
Vaccine, Reason 4 O O
please Reason 4 O O
visit: Reason 4 O O
[www.fluhd.ca](http://www.fluhd.ca/) Reason 4 O O
About O O O O
Sanofi O O O O
Sanofi, O O O O
a O O O O
global O O O O
healthcare O O O O
leader, O O O O
discovers, O O O O
develops O O O O
and O O O O
distributes O O O O
therapeutic O O O O
solutions O O O O
focused O O O O
on O O O O
patients' O O O O
needs. O O O O
Sanofi O O O O
is O O O O
organized O O O O
into O O O O
five O O O O
global O O O O
business O O O O
units: O O O O
Diabetes O O O O
and O O O O
Cardiovascular, O O O O
General O O O O
Medicines O O O O
and O O O O
Emerging O O O O
Markets, O O O O
Sanofi O O O O
Genzyme, O O O O
Sanofi O O O O
Pasteur O O O O
and O O O O
Merial. O O O O
Sanofi O O O O
is O O O O
in O O O O
New O O O O
York O O O O
(NYSE: O O O O
[SNY](http://en.sanofi.com/investors/share/stock_chart/stock_chart.aspx)). O O O O
Sanofi Reason 5 O O
Pasteur, Reason 5 O O
the Reason 5 O O
vaccines Reason 5 O O
division Reason 5 O O
of Reason 5 O O
Sanofi, Reason 5 O O
provides Reason 5 O O
more Reason 5 O O
than Reason 5 O O
1 Reason 5 O O
billion Reason 5 O O
doses Reason 5 O O
of Reason 5 O O
vaccine Reason 5 O O
each Reason 5 O O
year, Reason 5 O O
making Reason 5 O O
it Reason 5 O O
possible Reason 5 O O
to Reason 5 O O
immunize Reason 5 O O
more Reason 5 O O
than Reason 5 O O
500 Reason 5 O O
million Reason 5 O O
people Reason 5 O O
across Reason 5 O O
the Reason 5 O O
globe. Reason 5 O O
A Reason 4 O O
world Reason 4 O O
leader Reason 4 O O
in Reason 4 O O
the Reason 4 O O
vaccine Reason 4 O O
industry, Reason 4 O O
Sanofi Reason 4 O O
Pasteur Reason 4 O O
produces Reason 4 O O
a Reason 4 O O
portfolio Reason 4 O O
of Reason 4 O O
high Reason 4 O O
quality Reason 4 O O
vaccines Reason 4 O O
that Reason 4 O O
matches Reason 4 O O
its Reason 4 O O
areas Reason 4 O O
of Reason 4 O O
expertise Reason 4 O O
and Reason 4 O O
meets Reason 4 O O
public-health Reason 4 O O
demand. Reason 4 O O
The Reason 5 O O
company's Reason 5 O O
heritage, Reason 5 O O
to Reason 5 O O
create Reason 5 O O
vaccines Reason 5 O O
that Reason 5 O O
protect Reason 5 O O
life, Reason 5 O O
dates Reason 5 O O
back Reason 5 O O
more Reason 5 O O
than Reason 5 O O
a Reason 5 O O
century. Reason 5 O O
Sanofi Reason 4 O O
Pasteur Reason 4 O O
is Reason 4 O O
the Reason 4 O O
largest Reason 4 O O
company Reason 4 O O
entirely Reason 4 O O
dedicated Reason 4 O O
to Reason 4 O O
vaccines. Reason 4 O O
Every O O O O
day, O O O O
the O O O O
company O O O O
invests O O O O
more O O O O
than O O O O
EUR O O O O
1 O O O O
million O O O O
in O O O O
research O O O O
and O O O O
development. O O O O
For O O O O
more O O O O
information, O O O O
please O O O O
visit: O O O O
[www.sanofipasteur.ca](http://www.sanofipasteur.ca/). O O O O
References: O O O O
____________________________ O O O O
| O O O O
| O O O O
1 O O O O
Public O O ScientificAuthority O
Health O O ScientificAuthority O
Agency O O ScientificAuthority O
of O O ScientificAuthority O
Canada O O ScientificAuthority O
(2016). O O O O
An O O O O
Advisory O O O O
Committee O O O O
Statement O O O O
(ACS) O O O O
National O O O O
Advisory O O O O
Committee O O O O
on O O O O
Immunization O O O O
(NACI): O O O O
A O O O O
Review O O O O
of O O O O
the O O O O
Literature O O O O
of O O O O
High O O O O
Dose O O O O
Seasonal O O O O
Influenza O O O O
Vaccine O O O O
for O O O O
Adults O O O O
65 O O O O
Years O O O O
and O O O O
Older. O O O O
| O O O O
| O O O O
2 O O O O
Product O O O O
Monograph: O O O O
FLUZONE® O O O O
High-Dose O O O O
Influenza O O O O
Virus O O O O
Vaccine O O O O
Trivalent O O O O
Types O O O O
A O O O O
and O O O O
B O O O O
(Split O O O O
Virion). O O O O
Sanofi O O O O
Pasteur. O O O O
Approved O O O O
May O O O O
2016 O O O O
| O O O O
| O O O O
3 O O O O
Public O O O O
Health O O O O
Agency O O O O
of O O O O
Canada O O O O
(2016). O O O O
An O O O O
Advisory O O O O
Committee O O O O
Statement O O O O
(ACS) O O O O
National O O O O
Advisory O O O O
Committee O O O O
on O O O O
Immunization O O O O
(NACI): O O O O
Canadian O O O O
Immunization O O O O
Guide O O O O
Chapter O O O O
on O O O O
Influenza O O O O
and O O O O
Statement O O O O
on O O O O
Seasonal O O O O
Influenza O O O O
Vaccine O O O O
for O O O O
2016-2017. O O O O
| O O O O
| O O O O
4 O O O O
DiazGranados, O O O O
C.A. O O O O
et O O O O
al. O O O O
(2014). O O O O
Efficacy O O O O
of O O O O
high-dose O O O O
versus O O O O
standard-dose O O O O
influenza O O O O
vaccine O O O O
in O O O O
older O O O O
adults. O O O O
The O O O O
New O O O O
England O O O O
Journal O O O O
of O O O O
Medicine O O O O
371, O O O O
635-645. O O O O
| O O O O
| O O O O
5 O O O O
Centers O O ScientificAuthority O
of O O ScientificAuthority O
Disease O O ScientificAuthority O
Control O O ScientificAuthority O
and O O ScientificAuthority O
Prevention. O O ScientificAuthority O
People O O O O
at O O O O
High O O O O
Risk O O O O
of O O O O
Developing O O O O
Flu O O O O
Related O O O O
Complications. O O O O
| O O O O
| O O O O
6 O O O O
Udell O O O O
J.A., O O O O
et O O O O
al. O O O O
(2015). O O O O
Does O O O O
influenza O O O O
vaccination O O O O
influence O O O O
cardiovascular O O O O
complications? O O O O
Expert O O O O
Rev O O O O
Cardiovasc O O O O
Ther. O O O O
13:593-596. O O O O
| O O O O
| O O O O
*Against O O O O
lab-confirmed O O O O
influenza O O O O
illness O O O O
compared O O O O
to O O O O
a O O O O
standard O O O O
dose O O O O
influenza O O O O
vaccine O O O O
| O O O O
| O O O O
FLUZONE® O O O O
Influenza O O O O
Virus O O O O
Vaccine O O O O
Trivalent O O O O
Types O O O O
A O O O O
and O O O O
B O O O O
(Split O O O O
Virion) O O O O
| O O O O
| O O O O
FLUZONE® Reason 2 O O
High-Dose Reason 2 O O
Influenza Reason 2 O O
Vaccine Reason 2 O O
is Reason 2 O O
not Reason 2 O O
indicated Reason 2 O O
to Reason 2 O O
treat Reason 2 O O
or Reason 2 O O
prevent Reason 2 O O
heart Reason 2 O O
attacks Reason 2 O O
or Reason 2 O O
stroke. Reason 2 O O
SOURCE O O O O
Sanofi O O O O
Pasteur O O O O
Image O O O O
with O O O O
at: O O O O
[http://photos.newswire.ca/images/download/20161013_C7926_PHOTO_EN_794731.jpg](http://photos.newswire.ca/images/download/20161013_C7926_PHOTO_EN_794731.jpg) O O O O
or O O O O
to O O O O
arrange O O O O
an O O O O
interview, O O O O
please O O O O
contact: O O O O
Sanofi O O O O
